James George to Biomarkers
This is a "connection" page, showing publications James George has written about Biomarkers.
Connection Strength
0.297
-
Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood. 2016 10 27; 128(17):2175-2178.
Score: 0.107
-
Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins. Blood. 1990 Sep 01; 76(5):859-70.
Score: 0.070
-
The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: evaluation, management, and long-term outcomes experience of the Oklahoma TTP-HUS Registry, 1989-2007. Kidney Int Suppl. 2009 Feb; (112):S52-4.
Score: 0.063
-
Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy. Am J Hematol. 2016 06; 91(6):644-6.
Score: 0.026
-
Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol. 2009 Dec 01; 83(6):559-64.
Score: 0.016
-
Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol. 2008 Dec; 83(12):911-5.
Score: 0.016